In Re Elmar W. Weiler and Richard L. Mansell

790 F.2d 1576, 229 U.S.P.Q. (BNA) 673, 1986 U.S. App. LEXIS 20071
CourtCourt of Appeals for the Federal Circuit
DecidedMay 8, 1986
DocketAppeal 85-2085
StatusPublished
Cited by49 cases

This text of 790 F.2d 1576 (In Re Elmar W. Weiler and Richard L. Mansell) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Elmar W. Weiler and Richard L. Mansell, 790 F.2d 1576, 229 U.S.P.Q. (BNA) 673, 1986 U.S. App. LEXIS 20071 (Fed. Cir. 1986).

Opinion

*1578 MARKEY, Chief Judge.

Weiler and Mansell (Weiler) appeal from a decision of the United States Patent and Trademark Office Board of Appeals (board), App. No. 600-54 (Dec. 31, 1984), affirming the examiner’s rejection of claims 13 and 19 in a reissue application filed under 35 U.S.C. § 251 (1982). We affirm.

Background

Weiler filed an application on May 8, 1980, containing 11 claims. During prosecution, the examiner held that the application contained “three independent and distinct inventions” and required restriction between Claims 1-7 (assay method), Claims 8 and 11 (an “organic compound” in class 260/343.42), and Claims 9 and 10 (a “protein compound” in class 260/121). Weiler elected to prosecute Claims 1-7. Those claims were allowed without amendment, and the application issued on December 15, 1981 as U.S. Patent No. 4,305,923 (’923 patent) for a “Method for Quantitative Analysis for Limonin”.

1. U.S. Patent No. b,305,923

The seven claims of the patent are independent claim 1 and dependent claims 2-7. Claim 1 reads:

1. A method for quantitative analysis of limonin which comprises reacting a known amount of limonin-specific antibodies, with a mixture of a known volume of sample containing an unknown amount of limonin and a known amount of a limonin-derivative labeled with an enzyme or with a radioactive isotope, determining the amount of labeled limoninderivative which has reacted with said antibodies and calculating therefrom the unknown amount of limonin in said sample.

2. The Reissue Application

Weiler did not contest the examiner’s requirement for restriction and did not file a divisional application, to assert the non-elected claims or any other claims.

On August 18, 1982, Weiler filed application Serial No. 408,497 to reissue the ’923 patent. In his Declaration, Weiler said the ’923 patent was partly inoperative or invalid by reason of his having claimed less than he had a right to claim, and that that deficiency “exists because of errors which were made without deceptive intent on my part.”

Weiler alleged “an extraordinary sequence of events which preceded and followed the inadvertent abandonment of original claims 8-11” which made him aware that the invention of the ’923 patent was not adequately claimed. His Declaration set forth: (1) a June 23, 1981 letter from patent attorney Earl Tyner to Manzell (co-inventor of the ’923 invention) confirming Manzell’s authorization to file a divisional application on claims 8-11; (2) Tyner’s July 2, 1981 letter to Bryan Burgess (Office of General Counsel, University of Florida), about filing a divisional application; and (3) a January 19, 1982 letter to Mansell from Arthur Yeager, a partner in Tyner’s firm, stating that a divisional application had not been filed.

The Declaration further stated that “on being made aware of the failure to timely file the divisional application,” Mansell consulted with patent attorney William D. Stokes (counsel of record here), who drafted a set of claims which, he said in the Declaration, “should have been made in the original application.”

3. The Reissue Claims

The reissue application contained 20 claims. Claim 13 reads:

13. A method for developing citrus fruit strains low in limonin content, which method comprises identifying by the use of limonin-specific antibodies as a analytical reagent the limonin-low mutants in a breeding or cell culture program, and propagating said mutants.

Claim 19 reads:

19. A gamma gobulin fraction comprising antibodies reactive with limonin, said antibodies being formed consequent *1579 to injecting into an animal a limonin-protein conjugate.

Claims 1-12 and 20 were allowed by the examiner. Claim 2 was cancelled by Weiler. Claims 13-19 were rejected, and that rejection was appealed to the board.

4- The Board’s Action

The board agreed with the examiner’s view that “failure to timely file a divisional application including non-elected claims is a deliberate act and not error in the prosecution of the original patent” (citing In re Orita, 550 F.2d 1277, 193 USPQ 145 (CCPA 1977)). It sustained the rejection of claims 14-18 on that ground, i.e., because they are “directed to the same subject matter as the non-elected conjugate claims 9 and 10” of the original application. Claims 14-18 are not before us on appeal.

The board sustained the rejection of claims 13 and 19 on this specific ground:

Appeal claims 13 and 19 are directed to subject matter not claimed at all in the original application. As to them, the Examiner’s reliance on the case of In re Rowand et al. is entirely correct and that decision is controlling. Here, as in that case, “there is nothing in the original patent evidencing that appellants intended to claim (this now claimed subject matter)” (526 F.2d 558, 560, 187 USPQ 487 at 489).

Issue

Whether the board erred in sustaining the rejection of claims 13 and 19.

OPINION

Introduction

The starting place is the statute itself, 35 U.S.C. § 251:

Whenever any patent is, through error without any deceptive intention, deemed wholly or partly inoperative or invalid, by reason of a defective specification or drawing, or by reason of the patentee claiming more or less than he had a right to claim in the patent, the Commissioner shall, on surrender of such patent and the payment of the fee required by law, reissue the patent for the invention disclosed in the original patent, and in accordance with a new and amended application, for the unexpired part of the term of the original patent. No new matter shall be introduced into the application for reissue.

In enacting the statute, Congress provided a statutory basis for correction of “error”. The statute is remedial in nature, based on fundamental principles of equity and fairness, and should be construed liberally. In re Bennett, 766 F.2d 524, 528, 226 USPQ 413, 416 (Fed.Cir.1985) (in banc); Ball Corp. v. United States, 729 F.2d 1429, 1439 n. 28, 221 USPQ 289, 296 n. 28 (Fed. Cir.1984); In re Hay, 534 F.2d 917, 919, 189 USPQ 790, 791 (CCPA 1976). Nonetheless, not every event or circumstance that might be labeled “error” is correctable by reissue.

A. The Parties’ Contentions

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re MCDONALD
Federal Circuit, 2022
Antares Pharma, Inc. v. Medac Pharma Inc.
771 F.3d 1354 (Federal Circuit, 2014)
Antares Pharma, Inc. v. Medac Pharma, Inc.
55 F. Supp. 3d 526 (D. Delaware, 2014)
AstraZeneca UK Ltd. v. Aurobindo Pharma Ltd.
703 F.3d 511 (Federal Circuit, 2012)
In Re Yamazaki
702 F.3d 1327 (Federal Circuit, 2012)
In Re Tanaka
640 F.3d 1246 (Federal Circuit, 2011)
In Re Rosuvastatin Calcium Patent Litigation
719 F. Supp. 2d 388 (D. Delaware, 2010)
Pfizer Inc. v. Apotex Inc.
731 F. Supp. 2d 741 (N.D. Illinois, 2010)
In Re Arnold B. Serenkin
Federal Circuit, 2007
MBO Laboratories, Inc. v. Becton, Dickinson & Co.
474 F.3d 1323 (Federal Circuit, 2007)
Medrad, Inc. v. Tyco Healthcare Group Lp
466 F.3d 1047 (Federal Circuit, 2006)
Guidant Corp. v. St. Jude Medical, Inc.
409 F. Supp. 2d 543 (D. Delaware, 2006)
Medrad, Inc. v. Tyco Healthcare Group LP
391 F. Supp. 2d 374 (W.D. Pennsylvania, 2005)
Medtronic, Inc. v. Guidant Corp.
378 F. Supp. 2d 503 (D. Delaware, 2005)
Conmed Corp. v. Ludlow Corp.
235 F. Supp. 2d 109 (N.D. New York, 2002)
In Re Michael P. Doyle
293 F.3d 1355 (Federal Circuit, 2002)
VLT CORP. v. Unitrode Corp.
130 F. Supp. 2d 178 (D. Massachusetts, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
790 F.2d 1576, 229 U.S.P.Q. (BNA) 673, 1986 U.S. App. LEXIS 20071, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-elmar-w-weiler-and-richard-l-mansell-cafc-1986.